Sonire has developed Next Gen US-guided HIFU therapy system using technology and know-how generated by Tokyo Women’s Medical University, Tohoku University and Tokyo Medical University for cancer treatment. It is expected to be a new therapeutic modality for intractable cancer like pancreatic cancer.
We produce and provide homogeneous and high precision human blood cells to drastically streamline the evaluation of efficacy and safety of drug candidates and functional materials, as well as the research of infectious diseases. We also sell evaluation kits and offer various contract evaluation services.
CarbGeM aims to overcome the problem of antimicrobial resistance through cutting-edge biology and digital technology, cross-industrial and cross-disciplinary collaboration including medicine and engineering, and industry-government-academia collaboration with world leading hospitals and research institutions. Our AI-based product assists physicians and laboratory technicians in estimating the species of bacterial infections and selecting appropriate antimicrobial agents.
Celaid Therapeutics is an early stage Japan-based startup company that is based on the novel ex vivo expansion technology of hematopoietic stem cell invented at University of Tokyo and University of Tsukuba. Our mission is to develop cell therapy products that will be the next-generation stem cell transplantation.
A startup company from Keio University School of Medicine and Nagoya Institute of Technology, developing a visual restoration gene therapy using AAV (adeno-associated virus) vectors with the unique function gene “Chimeric Rhodopsin” to treat blindness.
The company is developing a unique microwave-excited surface wave plasma process to deposite graphene directly on aribrary susbtrates. Thus, the company gives various solutions for graphene formation on susbtrates like, plastics, glass, metals, dielectric and insulators. The graphene deposited technology has been extented to fabricate graphene-silicon solar cells, graphene coated peroveskite solar cells, all-solid-state lithium ion batteries and fuel cells.
We are a startup to develop a novel tiny particle for unmet medical needs such as cancer and chronic pain, which particle is self-targeting to the tumor vessel, repeatable and degradable as a platform technology for further applications. Our unique particle is patent granted in Japan, now under transferring to the US, EU and China now. The first indication for human clinical trial will be HCC (hepato-cellular carcinoma) to replace TACE (trans-catheter chemoembolization) treatment which is the current primary option for the intermediate stage of HCC and to be a primary option other than shifting to chemotherapy. The other advantages are universal to every solid tumor, locoregional work at tumor tissue only, combinatory because of drug free and gentle for the weaken patient without additional physical burden. We can expect the extension of PFS (progression free survival) and OS (overall survival) rather than the high response of the advanced chemotherapy such as molecular target medicine and immunotherapy with severe side effects and drug escalations. The potential market for liver cancer only will be near 1 billion dollars per year. So, after the extension to the other solid tumors, it will be easily over several billions. The current definition of our particle is a medical device (category III by FDA), but it can become a functional matter after labeling other functions as a medicine. We are looking for the investors, collaboration partners and medical institutions for the global clinical trials.
In Japan we suffer from a super-aging society. This aging population issue poses an urgent challenge to the medical sector. We need faster discharge rates at hospitals in order to stable revenue models and profitability. We can solve this problem with our proprietary technology - SAA.